OncRef

Clinical Trial: NCT06458712

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:Duke Street Bio Ltd
Information Provided By:Duke Street Bio Ltd
Last Update Posted:2026-09-02

Study Overview

Brief Summary

Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.

Official Title

Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy in Participants With Advanced Malignancies

Conditions

Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Intervention / Treatment

  • Drug: DSB2455

Other Study ID Numbers

  • DSB2455-001

Start Date (Actual)

2024-11-21

Primary Completion Date (Estimated)

2028-08

Study Completion Date (Estimated)

2028-12

Enrollment (Estimated)

180

Study Type

Interventional

Phase

Phase 1